Proimmune

Executive Summary

Proimmune is a UK-based biotechnology company founded in 2020 that provides advanced immunological reagents and services to accelerate immunology research from basic research through clinical development. The company's proprietary platforms, including Ankyrons® for target binding and MHC tetramers, offer unique solutions that reduce time and cost for clients in both academia and the pharmaceutical industry. Currently at Phase 1/2 stage, Proimmune is positioned to capitalize on the growing demand for immunology tools, though its early stage and lack of disclosed funding or revenue introduce uncertainty. The company's comprehensive suite of immunology assay services and focus on innovation suggest potential for strategic partnerships or licensing deals that could drive value.

Upcoming Catalysts (preview)

• Q4 2026License or partnership agreement for Ankyrons® platform60% success
• Q2 2027Completion of next funding round (Series A or B)50% success
• Q3 2026Release of case studies or data from client projects70% success